Literature DB >> 17712573

Use of chemotherapy at the end of life in a Portuguese oncology center.

José Ferraz Gonçalves1, Carmen Goyanes.   

Abstract

GOALS OF WORK: Chemotherapy plays a major role in the treatment of cancer. However, it is sometimes thought of as being taken too far, being used in many cases close to death. The purpose of this study is to determine the proximity of chemotherapy use to the patient's death in our hospital.
MATERIALS AND METHODS: This study comprised the analysis of the charts of 1,064 patients aged over 16 years with solid tumors who died in 2002 and were treated at the Porto Section of the Portuguese Institute of Oncology. MAIN
RESULTS: Four hundred ten of the 1,064 patients (39%) underwent chemotherapy. Fifty-two percent of those that underwent chemotherapy did so in the last 6 months of their lives, 31% in the last 3 months, 13% in the last month, and 3% in the last week. In the context of the total cohort of 1,064, the percentages of those that underwent chemotherapy was 20, 12, 5, and 1%, respectively. By multivariate analysis, age <65 years, breast and lung cancers, and metastases were positively associated with chemotherapy; kidney cancer and comorbidity were associated with a lower probability of undergoing chemotherapy. Three hundred sixty-one patients (34%) were admitted to the palliative care unit of the hospital.
CONCLUSION: It was concluded that in this hospital, chemotherapy is not used as close to death as often as most professionals feel and the literature reports. There are various possible explanations for this discrepancy; one of them may be the influence of health care systems. It would be useful to see what is happening in other countries with different health care systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712573     DOI: 10.1007/s00520-007-0316-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  16 in total

1.  Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.

Authors:  C Doyle; M Crump; M Pintilie; A M Oza
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

2.  Who gets chemotherapy for metastatic lung cancer?

Authors:  C C Earle; L N Venditti; P J Neumann; R D Gelber; M C Weinstein; A L Potosky; J C Weeks
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

3.  Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.

Authors:  M H Cullen; L J Billingham; C M Woodroffe; A D Chetiyawardana; N H Gower; R Joshi; D R Ferry; R M Rudd; S G Spiro; J E Cook; C Trask; E Bessell; C K Connolly; J Tobias; R L Souhami
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

4.  The influence of personal expectations on cancer patients' reports of health-related quality of life.

Authors:  G J Wan; M A Counte; D F Cella
Journal:  Psychooncology       Date:  1997-03       Impact factor: 3.894

5.  Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States.

Authors:  Linda C Harlan; Limin X Clegg; Edward L Trimble
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

Review 6.  A systematic review of physicians' survival predictions in terminally ill cancer patients.

Authors:  Paul Glare; Kiran Virik; Mark Jones; Malcolm Hudson; Steffen Eychmuller; John Simes; Nicholas Christakis
Journal:  BMJ       Date:  2003-07-26

7.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Authors:  D Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; C A Topham; L Awad; C Jacques; P Herait
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

8.  Chemotherapy use among Medicare beneficiaries at the end of life.

Authors:  Ezekiel J Emanuel; Yinong Young-Xu; Norman G Levinsky; Gail Gazelle; Olga Saynina; Arlene S Ash
Journal:  Ann Intern Med       Date:  2003-04-15       Impact factor: 25.391

9.  Someone to live for: social well-being, parenthood status, and decision-making in oncology.

Authors:  S B Yellen; D F Cella
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.

Authors:  P A Ellis; I E Smith; J R Hardy; M C Nicolson; D C Talbot; S E Ashley; K Priest
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

View more
  10 in total

1.  Chemotherapy in patients with advanced pancreatic cancer: too close to death?

Authors:  M Frigeri; S De Dosso; O Castillo-Fernandez; K Feuerlein; H Neuenschwander; P Saletti
Journal:  Support Care Cancer       Date:  2012-06-01       Impact factor: 3.603

2.  End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer.

Authors:  Yingming Zhu; Ke Tang; Fen Zhao; Yuanwei Zang; Xiaodong Wang; Zhenxiang Li; Xindong Sun; Jinming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-29       Impact factor: 4.553

3.  Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre.

Authors:  Alysson Wann; David Ashley; Mustafa Khasraw
Journal:  Support Care Cancer       Date:  2016-02-18       Impact factor: 3.603

4.  Parents' views of cancer-directed therapy for children with no realistic chance for cure.

Authors:  Jennifer W Mack; Steven Joffe; Joanne M Hilden; Jan Watterson; Caron Moore; Jane C Weeks; Joanne Wolfe
Journal:  J Clin Oncol       Date:  2008-09-08       Impact factor: 44.544

5.  Time from last chemotherapy to death and its correlation with the end of life care in a referral hospital.

Authors:  Syed Mustafa Karim; Jamal Zekri; Ehab Abdelghany; Reyad Dada; Husna Munsoor; Imran Ahmad
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

6.  Use of chemotherapy at the end of life in Turkey.

Authors:  Sema Sezgin Goksu; Seyda Gunduz; Dilek Unal; Mukremin Uysal; Deniz Arslan; Ali M Tatlı; Hakan Bozcuk; Mustafa Ozdogan; Hasan S Coskun
Journal:  BMC Palliat Care       Date:  2014-11-19       Impact factor: 3.234

7.  Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients.

Authors:  Ilaria Massa; Oriana Nanni; Flavia Foca; Marco Maltoni; Stefania Derni; Nicola Gentili; Giovanni Luca Frassineti; Andrea Casadei Gardini; Martina Valgiusti; Dino Amadori; Elena Prati; Mattia Altini; Davide Gallegati; Elisabetta Sansoni
Journal:  BMC Palliat Care       Date:  2018-06-19       Impact factor: 3.234

8.  Chemotherapy Use at the End of Life in Uganda.

Authors:  Daniel Low; Emily C Merkel; Manoj Menon; Gary H Lyman; Henry Ddungu; Elizabeth Namukwaya; Mhoira Leng; Corey Casper
Journal:  J Glob Oncol       Date:  2017-01-18

9.  Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study.

Authors:  Andrea A Martoni; Barbara Melotti; Claudia Degli Esposti; Vita Mutri; Giorgio Lelli; Silvia Ansaloni; Erico Piva; Elena Strocchi; Franco Pannuti
Journal:  ESMO Open       Date:  2017-03-14

Review 10.  Healthcare Received in the Last Months of Life in Portugal: A Systematic Review.

Authors:  Alexandra Pereira; Amélia Ferreira; José Martins
Journal:  Healthcare (Basel)       Date:  2019-10-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.